What if we could reprogramme the TME itself? Cutting-edge research suggests that engineered mesenchymal stem cells (MSCs) ...

Andrew Witty has resigned as chief executive of US health conglomerate UnitedHealth Group, as the company pulled its ...

It seems Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates for obesity and cardiometabolic ...

European Commission President Ursula von der Leyen has lost a lawsuit attempting to force her to disclose text messages with ...

GSK has agreed to pay $1.2 billion upfront to acquire rights to efimosfermin from Cambridge, Massachusetts-based Boston ...

The drive revolves around a "10-for-one" policy laid out in a Trump executive order at the end of January, which demanded ...

During the AAPS National Biotech Conference 2025, pharmaphorum’s Jonah Comstock sat down with Eric Luellen, the founder and CTIO of Turing Biosciences. Luellen shared the company's ambitious mission ...

Bayer chief executive Bill Anderson has said that newer product launches have offset the decline in sales of anticoagulant ...

The difference comes from the sourcing of raw materials and the functioning – and even nature – of supply chains. Because the ...

Reducing exposure to medicines is always a good thing if similar clinical outcomes can be achieved, and the study suggests it ...